Effect Of 17β-Estrdiol On MCF-7 And MDA-MB-231 Cell Lines On EGFR Expression

Abstract

In comparison to non-users, OCP users had a substantially higher incidence of breast tumors classified as Luminal B, Progesterone Receptor+ (PR+), and ER+. When comparing OCP users to nonusers, the age at admission for ER+ cancer was significantly lower in the former group (45.3 years) than in the latter (52.2 years). Alternatively, compared to non-users (45.4 years), patients with basal (TNBC) cancer who were OCP users were older at the time of admission (53.1 years). Logistic analysis showed that compared to non-users, OCP users had an 18% greater risk of TNBC and an 8% lower risk of ER+, PR+, and Luminal B, respectively, with each additional year of age. The in-vitro investigation found that the MDA-MB-231 cell line, when treated with β-estradiol and then chased with Cycloheximide, had a decreased expression of EGFR. It seems that estrogen destroys EGFR via the ubiquitination route, as EGFR expression did not decrease under treatment with MG-132 and E2. There may be a correlation between OCP usage and an uptick in ER+, PR+, and Luminal B breast cancer cases. In fact, there is some evidence that OCP usage is associated with a slowed advancement of TNBC. Results from an in vitro experiment showed that estrogen ubiquitinates EGFR in MDA-MB-231 cells, destroying the protein.